A Phase 4 interventional study of Eptinezumab and Erenumab in Migraine, sponsored by H. Lundbeck A/S. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.
Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 20th largest by enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 15th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 22nd largest by enrollment, is one of 3 that started in 2022, is one of 3 in phase 4, and was the 17th registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive eptinezumab via intravenous (IV) infusion on Day 0 and Day 84.
Drug: Eptinezumab
Participants are free to select treatment from one of 3 calcitonin gene-related peptide (CGRP) inhibitors: erenumab, fremanezumab, or galcanezumab. CGRP inhibitors will be administered via subcutaneous (SC) injection on Day 0 and then, per product label.
Drug: Erenumab · Drug: Fremanezumab · Drug: Galcanezumab
Onabotulinumtoxin-A will be administered via intramuscular (IM) injection on Day 0 and Day 84.
Drug: Onabotulinumtoxin-A
Concentrate for solution for IV infusion
Also known as: Vyepti
Solution for SC Injection
Also known as: Aimovig®
Solution for IM Injection
Solution for SC Injection
Also known as: Ajovy®
Solution for SC Injection
Also known as: Emgality®
Change From Baseline in Patient-informed Most Bothersome Symptom (PI-MBS) Score at Week 24
Participants select the symptom that they find most impairs them at the time of reporting and rate the severity of that symptom on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.
Time frame: Baseline, Week 24
Number of "Good Days" From Baseline
The participants report the number of "good days" and "bad days" they had in the previous week on a weekly basis using the good day/bad day scale.
Time frame: Up to Week 24
Change From Baseline in Quality of Life (QOL) as Measured by the 5 Level Euro Quality of Life 5 Dimensional Questionnaire (EQ-5D-5L) Score at Week 24
The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analog scale (VAS) of the overall health state. Each descriptive item is rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline, Week 24
Health Care Resources Utilization (HCRU): Number of Participants Who Used Health Services and Medications
Time frame: Up to Week 24
QOL as Measured by the 6 Item Headache Impact Test (HIT-6) Score
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item is rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 is the sum of each response score ranging from 36 to 78. The life impact derived from the total score is described as follows: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
Time frame: Up to Week 24
QOL as Measured by the Migraine Disability Assessment (MIDAS) Total Score
The Midas score is a participant completed 5-item questionnaire about lost time and productivity (for work, school or family/social activities) in the past 3 months (number of days missed) where: 0-5=Little or No disability, 6-10=Mild disability, 11-20=Moderate disability or 21+ Severe disability.
Time frame: Up to Week 24
Participant Satisfaction Score as Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)
The TSQM assesses four domains of participants' satisfaction with treatment, with scale ranges from 0 (extremely dissatisfied) to 100 (not at all dissatisfied) for each of the categories (Effectiveness, Side Effects, Convenience, and Overall Satisfaction).
Time frame: Week 24
Percentage of Participants That Switch From the Preventive Medication They Are Randomized to at Baseline to Another Preventive Medication
Time frame: Week 24
| Milestone | Erenumab | Fremanezumab | Onabotulinumtoxin-A | Galcanezumab | Eptinezumab |
|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 8 | 17 |
| Received at least 1 dose of study drug | 3 | 2 | 2 | 8 | 16 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 2 | 2 | 8 | 17 |
| Withdrew: Study terminated | 2 | 2 | 2 | 5 | 15 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 2 | 1 |
Participants select the symptom that they find most impairs them at the time of reporting and rate the severity of that symptom on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.
No measurements were reported for this outcome.
The participants report the number of "good days" and "bad days" they had in the previous week on a weekly basis using the good day/bad day scale.
No measurements were reported for this outcome.
The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analog scale (VAS) of the overall health state. Each descriptive item is rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).
No measurements were reported for this outcome.
No measurements were reported for this outcome.
The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item is rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 is the sum of each response score ranging from 36 to 78. The life impact derived from the total score is described as follows: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).
No measurements were reported for this outcome.
The Midas score is a participant completed 5-item questionnaire about lost time and productivity (for work, school or family/social activities) in the past 3 months (number of days missed) where: 0-5=Little or No disability, 6-10=Mild disability, 11-20=Moderate disability or 21+ Severe disability.
No measurements were reported for this outcome.
The TSQM assesses four domains of participants' satisfaction with treatment, with scale ranges from 0 (extremely dissatisfied) to 100 (not at all dissatisfied) for each of the categories (Effectiveness, Side Effects, Convenience, and Overall Satisfaction).
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over Baseline up to Week 24. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Erenumab | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Fremanezumab | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Onabotulinumtoxin-A | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Galcanezumab | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Eptinezumab | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Event | Erenumab | Fremanezumab | Onabotulinumtoxin-A | Galcanezumab | Eptinezumab |
|---|---|---|---|---|---|
| SinusitisInfections and infestations | 0/3 | 0/2 | 0/2 | 2/8 | 0/16 |
| COVID-19Infections and infestations | 0/3 | 0/2 | 0/2 | 1/8 | 0/16 |
| Upper respiratory tract infectionInfections and infestations | 0/3 | 0/2 | 0/2 | 1/8 | 1/16 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/2 | 0/2 | 1/8 | 1/16 |
| MigraineNervous system disorders | 0/3 | 0/2 | 0/2 | 1/8 | 0/16 |
| Attention deficit hyperactivity disorderPsychiatric disorders | 0/3 | 0/2 | 0/2 | 1/8 | 0/16 |
| Gastric ulcerGastrointestinal disorders | 0/3 | 0/2 | 0/2 | 0/8 | 1/16 |
| Pelvic floor dysfunctionGastrointestinal disorders | 0/3 | 0/2 | 0/2 | 0/8 | 1/16 |
| Facial painGeneral disorders | 0/3 | 0/2 | 0/2 | 0/8 | 1/16 |
| Swelling faceGeneral disorders | 0/3 | 0/2 | 0/2 | 0/8 | 1/16 |
All randomized participants.
| Age, Continuous(years) | Erenumab | Fremanezumab | Onabotulinumtoxin-A | Galcanezumab | Eptinezumab | Total |
|---|---|---|---|---|---|---|
| Mean | 47.3 ± 6.4 | 60.5 ± 4.9 | 30.5 ± 17.7 | 43.1 ± 12.6 | 38.2 ± 10.5 | 41.2 ± 12.1 |
| Sex: Female, Male(Participants) | Erenumab | Fremanezumab | Onabotulinumtoxin-A | Galcanezumab | Eptinezumab | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 2 | 2 | 6 | 15 | 28 |
| Male | 0 | 0 | 0 | 2 | 2 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Erenumab | Fremanezumab | Onabotulinumtoxin-A | Galcanezumab | Eptinezumab | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 0 | 1 | 5 | 9 |
| Not Hispanic or Latino | 1 | 1 | 2 | 7 | 12 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Erenumab | Fremanezumab | Onabotulinumtoxin-A | Galcanezumab | Eptinezumab | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 4 | 4 | 10 |
| White | 3 | 1 | 1 | 4 | 12 | 21 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2022 to primary completion in Feb 2023, 11 months.
Results were first posted in May 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eptinezumab · Erenumab · Onabotulinum toxin A · Fremanezumab · Galcanezumab